StockData
Altimmune, Inc. logo

Altimmune, Inc. (ALT) stock

ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$1.41+0.02 (+1.44%)

Close on Nov 19, 2026Market cap $274.27MP/E –Yield –

Altimmune gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Altimmune

Altimmune has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Altimmune figures

See a number that looks wrong?